GMED:NYSEGlobus Medical, Inc. Analysis

Globus Medical (GMED) combines a *27% year‑over‑year revenue surge* with an *impressive 68% gross margin* and *21% operating margin*, positioning it as a high‑quality growth business in the medical‑devices sector. The stock trades at a *trailing P/E of 17.9*, well below the industry average of 29.2, and a DCF‑derived fair value of **$93.3** suggests roughly a **40% upside** from the current price of $76.6. Analyst consensus (12 analysts) rates the company as a **Buy** with a mean target of $107.4, reinforcing the valuation case.
On the technical side, GMED is priced beneath its 20‑day (79.7), 50‑day (81.4) and 200‑day (82.3) moving averages, the MACD line sits under its signal, and the histogram is negative, all pointing to a *bearish short‑term trend*. However, the RSI of 42 indicates the stock is not yet oversold, and a rising volume trend could support a bounce from the near‑term support at $74.7. Volatility is elevated at **44.9%** over the past 30 days, while beta of 0.91 signals market‑relative moves are modest. Together, robust fundamentals and a sizable valuation gap outweigh the near‑term technical weakness, suggesting a buy‑on‑dip approach.